Chemotherapy targeting by DNA capture in viral protein particles

Hasmik Agadjanian, David Chu, Jae Youn Hwang, Sebastian Wachsmann-Hogiu, Altan Rentsendorj, Lei Song, Vinod Valluripalli, Jay Lubow, Jun Ma, Behrooz Sharifi, Daniel L. Farkas, Lali K. Medina-Kauwe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: This study tests the hypothesis that DNA intercalation and electrophilic interactions can be exploited to noncovalently assemble doxorubicin in a viral protein nanoparticle designed to target and penetrate tumor cells through ligand-directed delivery. We further test whether this new paradigm of doxorubicin targeting shows therapeutic efficacy and safety in vitro and in vivo. Materials and methods: We tested serum stability, tumor targeting and therapeutic efficacy in vitro and in vivo using biochemical, microscopy and cytotoxicity assays. Results: Self-assembly formed approximately 10-nm diameter serum-stable nanoparticles that can target and ablate HER2+ tumors at >10× lower dose compared with untargeted doxorubicin, while sparing the heart after intravenous delivery. The targeted nanoparticle tested here allows doxorubicin potency to remain unaltered during assembly, transport and release into target cells,while avoiding peripheral tissue damage and enabling lower, and thus safer, drug dose for tumor killing. Conclusion: This nanoparticle may be an improved alternative to chemical conjugates and signal-blocking antibodies for tumor-targeted treatment.

Original languageEnglish (US)
Pages (from-to)335-352
Number of pages18
JournalNanomedicine
Volume7
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

chemotherapy
Chemotherapy
Viral Proteins
tumor
Virion
targeting
Tumors
DNA
Nanoparticles
Doxorubicin
Proteins
Drug Therapy
protein
Neoplasms
damages
paradigm
serum
drug
interaction
Blocking Antibodies

Keywords

  • doxorubicin
  • HER
  • herdox
  • nanoparticle
  • noncovalent
  • penton base
  • self-assembly
  • tumor targeting
  • viral capsid

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

Agadjanian, H., Chu, D., Hwang, J. Y., Wachsmann-Hogiu, S., Rentsendorj, A., Song, L., ... Medina-Kauwe, L. K. (2012). Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine, 7(3), 335-352. https://doi.org/10.2217/nnm.11.104

Chemotherapy targeting by DNA capture in viral protein particles. / Agadjanian, Hasmik; Chu, David; Hwang, Jae Youn; Wachsmann-Hogiu, Sebastian; Rentsendorj, Altan; Song, Lei; Valluripalli, Vinod; Lubow, Jay; Ma, Jun; Sharifi, Behrooz; Farkas, Daniel L.; Medina-Kauwe, Lali K.

In: Nanomedicine, Vol. 7, No. 3, 03.2012, p. 335-352.

Research output: Contribution to journalArticle

Agadjanian, H, Chu, D, Hwang, JY, Wachsmann-Hogiu, S, Rentsendorj, A, Song, L, Valluripalli, V, Lubow, J, Ma, J, Sharifi, B, Farkas, DL & Medina-Kauwe, LK 2012, 'Chemotherapy targeting by DNA capture in viral protein particles', Nanomedicine, vol. 7, no. 3, pp. 335-352. https://doi.org/10.2217/nnm.11.104
Agadjanian H, Chu D, Hwang JY, Wachsmann-Hogiu S, Rentsendorj A, Song L et al. Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine. 2012 Mar;7(3):335-352. https://doi.org/10.2217/nnm.11.104
Agadjanian, Hasmik ; Chu, David ; Hwang, Jae Youn ; Wachsmann-Hogiu, Sebastian ; Rentsendorj, Altan ; Song, Lei ; Valluripalli, Vinod ; Lubow, Jay ; Ma, Jun ; Sharifi, Behrooz ; Farkas, Daniel L. ; Medina-Kauwe, Lali K. / Chemotherapy targeting by DNA capture in viral protein particles. In: Nanomedicine. 2012 ; Vol. 7, No. 3. pp. 335-352.
@article{2f96ba6b01ff4ef2a6709870c9250326,
title = "Chemotherapy targeting by DNA capture in viral protein particles",
abstract = "Aim: This study tests the hypothesis that DNA intercalation and electrophilic interactions can be exploited to noncovalently assemble doxorubicin in a viral protein nanoparticle designed to target and penetrate tumor cells through ligand-directed delivery. We further test whether this new paradigm of doxorubicin targeting shows therapeutic efficacy and safety in vitro and in vivo. Materials and methods: We tested serum stability, tumor targeting and therapeutic efficacy in vitro and in vivo using biochemical, microscopy and cytotoxicity assays. Results: Self-assembly formed approximately 10-nm diameter serum-stable nanoparticles that can target and ablate HER2+ tumors at >10× lower dose compared with untargeted doxorubicin, while sparing the heart after intravenous delivery. The targeted nanoparticle tested here allows doxorubicin potency to remain unaltered during assembly, transport and release into target cells,while avoiding peripheral tissue damage and enabling lower, and thus safer, drug dose for tumor killing. Conclusion: This nanoparticle may be an improved alternative to chemical conjugates and signal-blocking antibodies for tumor-targeted treatment.",
keywords = "doxorubicin, HER, herdox, nanoparticle, noncovalent, penton base, self-assembly, tumor targeting, viral capsid",
author = "Hasmik Agadjanian and David Chu and Hwang, {Jae Youn} and Sebastian Wachsmann-Hogiu and Altan Rentsendorj and Lei Song and Vinod Valluripalli and Jay Lubow and Jun Ma and Behrooz Sharifi and Farkas, {Daniel L.} and Medina-Kauwe, {Lali K.}",
year = "2012",
month = "3",
doi = "10.2217/nnm.11.104",
language = "English (US)",
volume = "7",
pages = "335--352",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Chemotherapy targeting by DNA capture in viral protein particles

AU - Agadjanian, Hasmik

AU - Chu, David

AU - Hwang, Jae Youn

AU - Wachsmann-Hogiu, Sebastian

AU - Rentsendorj, Altan

AU - Song, Lei

AU - Valluripalli, Vinod

AU - Lubow, Jay

AU - Ma, Jun

AU - Sharifi, Behrooz

AU - Farkas, Daniel L.

AU - Medina-Kauwe, Lali K.

PY - 2012/3

Y1 - 2012/3

N2 - Aim: This study tests the hypothesis that DNA intercalation and electrophilic interactions can be exploited to noncovalently assemble doxorubicin in a viral protein nanoparticle designed to target and penetrate tumor cells through ligand-directed delivery. We further test whether this new paradigm of doxorubicin targeting shows therapeutic efficacy and safety in vitro and in vivo. Materials and methods: We tested serum stability, tumor targeting and therapeutic efficacy in vitro and in vivo using biochemical, microscopy and cytotoxicity assays. Results: Self-assembly formed approximately 10-nm diameter serum-stable nanoparticles that can target and ablate HER2+ tumors at >10× lower dose compared with untargeted doxorubicin, while sparing the heart after intravenous delivery. The targeted nanoparticle tested here allows doxorubicin potency to remain unaltered during assembly, transport and release into target cells,while avoiding peripheral tissue damage and enabling lower, and thus safer, drug dose for tumor killing. Conclusion: This nanoparticle may be an improved alternative to chemical conjugates and signal-blocking antibodies for tumor-targeted treatment.

AB - Aim: This study tests the hypothesis that DNA intercalation and electrophilic interactions can be exploited to noncovalently assemble doxorubicin in a viral protein nanoparticle designed to target and penetrate tumor cells through ligand-directed delivery. We further test whether this new paradigm of doxorubicin targeting shows therapeutic efficacy and safety in vitro and in vivo. Materials and methods: We tested serum stability, tumor targeting and therapeutic efficacy in vitro and in vivo using biochemical, microscopy and cytotoxicity assays. Results: Self-assembly formed approximately 10-nm diameter serum-stable nanoparticles that can target and ablate HER2+ tumors at >10× lower dose compared with untargeted doxorubicin, while sparing the heart after intravenous delivery. The targeted nanoparticle tested here allows doxorubicin potency to remain unaltered during assembly, transport and release into target cells,while avoiding peripheral tissue damage and enabling lower, and thus safer, drug dose for tumor killing. Conclusion: This nanoparticle may be an improved alternative to chemical conjugates and signal-blocking antibodies for tumor-targeted treatment.

KW - doxorubicin

KW - HER

KW - herdox

KW - nanoparticle

KW - noncovalent

KW - penton base

KW - self-assembly

KW - tumor targeting

KW - viral capsid

UR - http://www.scopus.com/inward/record.url?scp=84857802702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857802702&partnerID=8YFLogxK

U2 - 10.2217/nnm.11.104

DO - 10.2217/nnm.11.104

M3 - Article

VL - 7

SP - 335

EP - 352

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 3

ER -